SCHEMBL21383033

SCHEMBL21383033

CCCCC=Cc1ccccc1C[SiH2]Br

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYSLTR2 Q9NS75 2/20 0.36
CYSLTR1 Q9Y271 2/20 0.36
PDE5A O76074 1/20 0.36
BID P55957 3/20 0.33
BCL2L1 Q07817 3/20 0.33
MCL1 Q07820 3/20 0.33
BAK1 Q16611 3/20 0.33
TLR8 Q9NR97 1/20 0.33
OXER1 Q8TDS5 1/20 0.31
PPARD Q03181 1/20 0.30
MMP2 P08253 2/20 0.30
F7 P08709 2/20 0.30
F3 P13726 2/20 0.30
ALDH1A1 P00352 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2C9 P11712 1/20 0.30
TSHR P16473 1/20 0.30
CYP2C19 P33261 1/20 0.30
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21383361 0.84 CYSLTR2 (0.36) CYSLTR2CYSLTR1PDE5ABIDBCL2L1
SCHEMBL5033527 0.82 PDE5A (0.43) CYSLTR2CYSLTR1PDE5ABIDBCL2L1
SCHEMBL27892530 0.80 BID (0.41) CYSLTR2CYSLTR1PDE5ABIDBCL2L1
SCHEMBL9802025 0.78 LIPG (0.49) CYSLTR2CYSLTR1BIDBCL2L1MCL1
SCHEMBL9802035 0.78 LIPG (0.49) CYSLTR2CYSLTR1BIDBCL2L1MCL1
SCHEMBL27876083 0.76 F7 (0.47) CYSLTR2CYSLTR1BIDBCL2L1MCL1
SCHEMBL21383266 0.75 CYSLTR2 (0.36) CYSLTR2CYSLTR1PDE5ABIDBCL2L1
SCHEMBL676290 0.74 CYSLTR2 (0.43) CYSLTR2CYSLTR1PDE5ABIDBCL2L1
SCHEMBL27875985 0.74 F7 (0.49) CYSLTR2CYSLTR1BIDBCL2L1MCL1
SCHEMBL3269456 0.74 PDE5A (0.50) CYSLTR2CYSLTR1PDE5ABIDBCL2L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3768732-A1 PROCESS FOR FUNCTIONALIZATION OF ORGANO-ZINC COMPOUNDS WITH HALOSILANES USING BASIC NITROGEN CONTAINING HETEROCYCLES AND SILYL-FUNCTIONALIZED COMPOUNDS PREPARED THEREBY Dow Global Technologies LLC (US) 2021-01-27 EP disclosed
EP-3768733-A1 SILICON-TERMINATED TELECHELIC POLYOLEFIN COMPOSITIONS AND PROCESSES FOR PREPARING THE SAME Dow Global Technologies LLC (US) 2021-01-27 EP disclosed
US-20210017195-A1 PROCESS FOR FUNCTIONALIZATION OF ORGANO-ZINC COMPOUNDS WITH HALOSILANES USING BASIC NITROGEN CONTAINING HETEROCYCLES AND SILYL-FUNCTIONALIZED COMPOUNDS PREPARED THEREBY DOW GLOBAL TECHNOLOGIES LLC (US) 2021-01-21 US disclosed
US-20210017311-A1 SILICON-TERMINATED TELECHELIC POLYOLEFIN COMPOSITIONS AND PROCESSES FOR PREPARING THE SAME DOW GLOBAL TECHNOLOGIES LLC 2021-01-21 US disclosed
CN-111868110-A Silicon-terminated telechelic polyolefin compositions and methods of making the same 陶氏环球技术有限责任公司 2020-10-30 CN disclosed
WO-2019182992-A1 PROCESS FOR FUNCTIONALIZATION OF ORGANO-ZINC COMPOUNDS WITH HALOSILANES USING BASIC NITROGEN CONTAINING HETEROCYCLES AND SILYL-FUNCTIONALIZED COMPOUNDS PREPARED THEREBY DOW GLOBAL TECHNOLOGIES LLC (US) 2019-09-26 WO disclosed
WO-2019182993-A1 SILICON-TERMINATED TELECHELIC POLYOLEFIN COMPOSITIONS AND PROCESSES FOR PREPARING THE SAME DOW GLOBAL TECHNOLOGIES LLC (US) 2019-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210017195-A1 PROCESS FOR FUNCTIONALIZATION OF ORGANO-ZINC COMPOUNDS WITH HALOSILANES USING BASIC NITROGEN CONTAINING HETEROCYCLES AND SILYL-FUNCTIONALIZED COMPOUNDS PREPARED THEREBY ZRANB2, NISCH, ZKSCAN2 CYSLTR2 2653/4885CYSLTR1 3032/4885PDE5A 4884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.